ReviewCureus2025
Thalamic Arteriovenous Malformations: A Systematic Review of Presentation, Diagnostic Modalities, and Treatment Approaches.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thalamic arteriovenous malformations (AVMs) are rare, deep-seated vascular lesions associated with a high risk of hemorrhage and significant neurological deficits. Due to their complex anatomy, these lesions present unique challenges in management. Various therapeutic approaches, including microsurgical resection, stereotactic radiosurgery, and embolization, have been employed to address these challenges. This systematic review examines the clinical presentation, diagnostic modalities, treatment outcomes, and complications associated with thalamic AVMs. A comprehensive literature search was conducted in PubMed, Scopus, and Rayyan databases, focusing on studies reporting clinical outcomes of patients with thalamic AVMs. Eligible studies included those assessing treatment outcomes for surgical resection, stereotactic radiosurgery (SRS), and embolization. Data extraction and risk of bias assessments were performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Nineteen studies, comprising a total of 97 patients, were included. Radiosurgery was the most frequently employed treatment, with obliteration rates ranging from 66.7% to 82%, though it carried a risk of post-treatment complications such as rebleeding (5.9%) and neurological deficits (17%). Microsurgery achieved obliteration rates of up to 71%, but this was associated with significant perioperative risks. In comparison, radiosurgery demonstrated obliteration rates ranging from 66.7% to 82%, offering a balance between safety and efficacy for most patients. Embolization, though less commonly used, showed promise in select cases, while conservative management was effective for patients in whom surgery posed an excessive risk. The management of thalamic AVMs is multidisciplinary, with treatment decisions tailored to individual AVM characteristics, patient status, and risk profiles over time. Microsurgical resection remains an option for cases requiring immediate intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.